Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2012

Jun 8, 2012

151_ip_2012-06-08_15a685c0-6250-4ad1-9519-00ca9495295c.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Best in Class Drug Discovery solutions -Evotec Company Overview

Evotec AG, Jefferies 2012 Global Healthcare Conference, 4-7 June 2012

Forward-looking s statements

Information set forth in this presen forward-looking statements, which invo risks and uncertainties ncertainties. The forward forward-lo contained herein represent the judgemen the date of this presentation. Such statements are neither promises nor gua subject to a variety of risks and uncert which are beyond our control control, and wh ntation containsolve a number ofoking statements nt of Evotec as offorward-looking arantees, but are tainties, many of hich couldcause

actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim an obligation or ndertaking to release p blicl any undertakingpublicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Agenda

• Evotec at a glance

  • Action Plan 2016 Innovation Efficiency
  • Financial strategy & Outlook

Leader in Innovati on Efficiency

Evotec at a glance 1)

3 1) Founded in 1993, Publicly listed on TecDAX (Germany) ), approx. 70% free float, >600 employees, Headquarter in Hamburg, Germany

Solutions to accelerate Innovation Efficiency

Evotec overview

Agenda

  • Evotec at a glance
  • Action Plan 2016 Innovation Efficiency
  • Financial strategy & Outlook

External innovatiohigher capital effic on delivers ciency

Key factors underpinning Evotec's mission

Action Plan 2016 f for sustainable growth

Action Plan 2016 - Forcesat work

Leveraging innovation efficient discovery

Action Plan 2016 - Evotec's offering for Innovation Efficiency

Broad stand alonee execution business

Comprehensive Drug Disc covery Platform – "EVO Apps"

Disease biology is the processor for integrated drug discovery alliances

Alliance model

"Faster to Decisioaligns incentives ns" business model

Business model

Strong portfolio of f top-class partners

Selected integrated drug d discovery alliances – targets provided by partners

P
t
a
r
n
e
r
s		 F
o
c
u
s
a
r
e
a		 f
U
i
d
E
t
p
s
e
o
r
v
v
o
e
c		 D
i
i
t
e
s
c
r
p
o
n
O
l
n
c
o
o
g
y,
f
i
l
i
t
n
a
m
m
a
o
n		 +
+
+		 f
P
b
d
l
i-
l
t
t
t
t
e
r
o
r
m
a
n
c
e
a
s
e
m
u
a
r
g
e
o
n
g
e
r
m
-
-
,
l
l
i
a
a
n
c
e
H
i
d
i
t
t
n
n
g
o
n
s
e
a
s
e
u		 + L
l
l
l
l
i
i
f
d
h
h
f
i
h
t
t
t
t
t
o
n
g
e
e
r
r
m
m
a
a
a
a
n
n
c
c
e
e
o
c
s
e
o
n
e
e
g
u
-
,
i
H
i
d
i
t
t
t
a
g
a
n
s
n
n
g
o
n
s
e
a
s
e
u
V
i
a
r
o
u
s		 +
+		 f
L
l
l
i
d
l
i
l
t
t
t
t
o
n
g
e
r
m
a
a
n
c
e
o
c
u
s
e
o
n
m
u
p
e
a
r
g
e
s
-
,
C
S
N
1
I
l
2
m
m
n
o
o
g
u
y		 +
+		 P
f
b
d
l
l
l
i
t
e
r
o
r
m
a
n
c
e
a
s
e
o
n
g
e
r
m
a
a
n
c
e
-
-
,
,
C
S
/
f
d
N
I
l
t
t
o
c
s
e
o
n
m
m
n
o
o
g
g
a
r
e
s
u
u
y
P
i
a
n		 +
+		 P
f
b
d
l
l
i
f
d
i
e
r
o
r
m
a
n
c
e
a
s
e
a
a
n
c
e
o
c
s
e
o
n
p
a
n
u
-
,
V
i
a
r
o
u
s		 +
+		 f
P
b
d
l
i-
l
t
t
t
t
e
r
o
r
m
a
n
c
e
a
s
e
m
u
a
r
g
e
o
n
g
e
r
m
-
-
,
l
l
i
a
a
n
c
e

Good Phase III pro EVT 401 back in deog pp ress on Diapep277, evelopment pipeline

Portfolio of product develo opment partnerships

I
I
d
d
i
i
i
i
t
t
n
c
a
o
n		 P
t
a
r
n
e
r		 S
S
t
t
t
t
a
s
u		 N
t
e
x
i
l
t
m
e
s
o
n
e		 C
i
i
l
l
o
m
m
e
r
c
a
s
)
1
D
i
b
t
a
e
e
s		 d
P
h
I
I
2
n
a
s
e
i
i
t
r
e
c
r
n
g
u		 F
i
l
P
h
I
I
I
I
n
a
a
s
e
d
t
a
a		 A
€
4
0
i
l
t
p
p
r
o
x.
m
m
e
s
o
n
e
s,
l
i
i
l
k
t
t
t
t
r
o
y
a
e
s
p
o
e
n
a
m
a
r
e
;
€
5
0
0
a
p
p
r
o
x.
m
A
l
h
i
´s
e
m
e
r
z
2
)
D
i
s
e
a
s
e		 P
h
I
I
a
s
e		 P
h
I
I
b
a
s
e
i
i
i
i
t
t
n
a
o
n		 \$
A
8
2
0
p
p
r
o
m
x.
i
l
l
i
t
t
m
e
s
o
n
e
s,
r
o
a
e
s
y
;
\$
i
l
k
b
3–
5
t
t
t
p
o
e
n
a
m
a
r
e
n
T
T
i
t
t
t
t
t
t
r
r
e
e
a
a
m
m
e
e
n
n
r
e
s
s
a
n
)
3
d
i
e
p
r
e
s
s
o
n		 O
O
p
e
n		 P
h
I
I
a
s
e		 N
N
i
t
e
e
w
p
a
r
n
e
r
n
g		 O
p
e
n
)
4
I
i
n
s
o
m
n
a		 P
h
I
I
a
s
e		 P
h
I
I
b
t
t
a
s
e
s
a
r		 M
i
l
l
i
t
t
e
s
o
n
e
s,
r
o
y
a
e
s
I
f
l
i
t
n
a
m
m
a
o
n
(
P
X
)
2
7		 C
O
N
B
A
P
H
A
R
M
A		 /
P
h
I
I
I
a
s
e		 P
h
I
I
t
t
a
s
e
s
a
r		 A
i
l
6
0
t
p
p
r
o
x.
m
m
e
s
o
n
e
s,
l
i
t
r
o
y
a
e
s
;
I
f
l
i
i
t
n
a
m
m
a
o
n
n
)
5
i
l
h
l
h
t
a
n
m
a
e
a		 P
h
I
/
I
I
a
s
e		 P
h
I
I
a
s
e
t
t
s
a
r		 M
i
l
l
i
t
t
e
s
o
n
e
s,
r
o
y
a
e
s
6
)
O
h
t
e
r
s		 O
p
e
n		 P
l
i
i
l
r
e-
c
n
c
a		 P
i
t
a
r
n
e
r
n
g		 O
p
e
n

Novel treatment fomet Phase III endp or T1D points

Product development allia ance with Andromeda/Teva (Phase III)

About DiaPep 277®

  • • DiaPep 277®, is a unique peptide of 24 amino acids, d derived from human heat shock protein 60 (HSP 60)
  • • The peptide acts by modulating the immune system, t that secrete insulin in response to elevated blood gluc thus preventing the destruction of pancreatic cells cose levels

DiaPep 277® is pro entry; orphan drug og g ressing towards market g status in USA granted

Example 1: Product develo opment alliance with Andromeda/Teva

D
l
b
k
d
t
e
v
e
o
p
m
e
n
a
c
g
g
r
o
u
n		 S
t
t
a
u
s		 E
d
k
i
l
t
t
p
e
c
e
e
m
e
s
o
n
e
s
x
y
f
E
t
o
r
o
e
c
v
A
l
l
d
l
l
t,
t
e
e
o
p
m
e
n
r
e
g
a
o
r
v
u
y
•
i
b
i
l
i
i
d
h
t
t
r
e
s
p
o
n
s
e
s
a
n
c
o
s
s
a
e
v
b
f
d
t
t
e
e
n
r
a
n
s
e
r
r
e
o
1
)
/
A
d
d
T
n
r
o
m
e
a
e
a
v
P
h
I
d
P
h
I
I
d
i
t
a
s
e
a
n
a
s
e
s
u
e
s
•
f
f
l
l
l
l
d
d
d
d
t
t
w
e
r
e
s
u
c
c
e
s
s
u
y
c
o
n
u
c
e
T
P
h
I
I
I
d
i
h
t
t
o
a
s
e
s
e
s
a
e
o
w
u
v
•
b
d
d
f
i
i
t
t
t
e
c
o
n
c
e
o
r
r
e
g
s
r
a
o
n
u
T
h
l
d
i
d
e
v
a
a
s
a
w
o
r
w
e
•
l
i
l
i
t
e
c
s
e
c
e
n
s
e
o
x
u
v
®
D
i
P
2
7
7
a
e
p
p		 ®
D
i
P
i
2
7
7
t
a
e
p
m
m
e
p
r
m
a
r
y
•
t
d
i
f
P
h
I
I
I
i
l
1
t
s
t
e
n
p
o
n
o
a
s
e
r
a
(
B
l
l
f
i
)
d
t
t
t
e
a
c
e
n
c
o
n
a
n
u
i
d
€
i
l
3
9
9
t
t
r
g
g
e
r
e
a
m
m
e
s
o
n
e
®
D
i
P
2
d
d
d
7
7
t
t
a
e
p
e
m
o
n
s
r
a
e
a
•
i
i
i
i
f
f
i
i
i
i
f
f
t
t
t
t
s
g
n
c
a
n
p
r
e
s
s
e
r
v
a
o
n
o
C
i
d
l
l
l
k
f
t
-p
e
p
e
e
v
e
s
a
m
a
r
e
r
o
r
,
i
i
l
i
i
b
t
a
s
s
e
s
s
n
g
n
s
n
s
e
c
r
e
o
n
u
y
i
l
l
t
p
a
n
c
r
e
a
c
c
e
s
s
f
A
d
d
i
i
l
l
i
i
l,
d
t
t
o
n
a
c
n
c
c
a
s
a
e
y
a
n
•
f
f
i
l
i
i
e
c
a
c
y
a
n
a
y
s
s
o
n
g
o
n
g
d
P
h
I
I
I
i
h
2
5
0
0
n
t
a
s
e
a
p
p
r
o
w
x
•
i
l
d
i
i
i
d
t
t
t
t
p
a
e
n
s
a
s
a
r
e
a
n
a
e
w
y		 N
i
l
i
i
d
t
t
t
e
m
e
s
o
n
e
s
r
g
g
e
r
e
x
•
d
l
i
f
P
h
2
t
n
p
o
n
c
o
m
p
e
o
n
o
a
s
e
u
I
I
I
d
t
s
u
y
d
f
F
i
l
d
2
P
h
I
I
I
i
t
n
n
a
a
a
o
a
s
e
n
•
/
(
)
2
0
1
4
2
0
1
5
e
F
i
l
j
d
f
t
t
r
s
s
a
e
s
p
r
o
e
c
e
o
r
•
(
)
/
2
0
1
2
0
1
6
5
e

Novel treatment off Alzheimer's disease

Product development allia ance with Roche (Phase II)

E
V
T
3
0
2
l
l
i
M
A
O
B
i
h
i
b
i
l
d
d
i
f
t
t
t
a
n
o
r
a
y
a
c
v
e
n
o
r
o
s
o
w
o
w
n
p
r
o
g
r
e
s
s
o
n
o
–
-
)
(
A
l
h
i
'
d
i
A
D
z
e
m
e
r
s
s
e
a
s
e
(
)
f
f
f
A
l
h
i
d
i
A
D
i
h
d
i
A
D
t
t
t
t
t
z
e
m
e
r
s
e
a
s
e
s
e
m
o
s
c
o
m
m
o
n
o
r
m
o
e
m
e
n
a
m
o
s
o
e
n
•
,
i
d
i
d
i
l
6
5
s
a
g
n
o
s
e
n
p
e
o
p
e
o
v
e
r
f
T
h
i
h
d
i
h
i
h
i
A
D
i
t
t
e
r
e
s
n
o
c
u
r
e
o
r
e
s
e
a
s
e
w
c
w
o
r
s
e
n
s
a
s
p
r
o
g
r
e
s
s
e
s
s
•
,
f
f
d
i
d
1
i
8
0
l
b
2
0
0
t
t
t
5
p
r
e
c
e
o
a
e
c
n
p
e
o
p
e
y
G
f
R
1
E
V
T
3
0
2
i
d
l
d
h
A
D
5
7
7
t
t
t
t
t
s
o
o
n
e
s
m
p
o
m
s
o
s
a
r
g
e
e
o
w
w
y
y
•
–
).
1
S
T
h
i
l
d
b
d
d
i
i
i
h
A
D
A
t
t
t
t
t
s
w
o
u
e
e
m
o
n
s
r
a
e
n
c
o
g
n
v
e
e
s
s
s
u
c
a
s
-c
o
g

About RG 1577– EVT 302

  • • MAO-B is normally present in brain and is responsible e for break-down of certain neurotransmitters
  • • Activity of MAO-B is linked to production roduction of reactive eactiveo damage oxygen species, molecules oleculesthat can cause neuronal euronal
  • • Blocking the activity of MAO-B should reduce oxidativ ve stress which is expected to slow progression of AD

RG 1577/EVT302 –high unmet medical need

Example 2: Product develo opment alliance with Roche

D
l
b
k
d
t
e
e
o
p
m
e
n
a
c
g
g
r
o
n
v
u		 L
i
i
t
c
e
n
s
n
g
g
a
g
g
r
e
e
e
m
e
n		 S
d
d
k
t
t
t
a
u
s
a
n
e
x
p
e
c
e
e
y
i
l
f
E
t
t
m
e
s
o
n
e
s
o
r
v
o
e
c
A
l
l
d
l
l
t,
t
e
e
o
p
m
e
n
r
e
g
a
o
r
v
u
y
•
i
b
i
l
i
i
d
h
t
t
r
e
s
p
o
n
s
e
s
a
n
c
o
s
s
a
e
v
b
f
d
R
h
t
t
e
e
n
r
a
n
s
e
r
r
e
o
o
c
e
P
h
I
d
P
h
I
I
i
l
t
a
s
e
a
n
a
s
e
r
a
s
•
h
b
d
d
i
l
l
t
t
a
e
e
e
n
c
o
n
c
e
p
a
r
a
v
u
y
f
f
i
h
d
i
h
i
l
t
t
t
t
w
e
r
e
n
e
r
a
p
e
u
c
g
o
a
s
S
f
f
i
l
i
b
l
i
h
d
t
t
a
e
y
p
r
o
e
s
e
s
a
s
e
•
f
D
l
i
l
t
e
v
e
o
p
m
e
n
p
r
o
e
c
a
n
•
i
l
l
d
l
t
t
t
t
t
p
o
e
n
a
y
a
r
g
e
s
a
n
a
o
n
e
l
i
i
t
t
t
t
a
p
p
c
a
o
n
o
r
r
e
a
m
e
n
s		 N
f
h
E
t
t
t
t
o
r
e
r
c
o
s
s
o
o
e
c
u
v
•
\$
U
f
f
1
0
t
t
p
r
o
n
p
a
y
m
e
e
n
o
m
•
\$
M
i
l
f
8
2
0
t
e
s
o
n
e
s
o
m
•
D
b
l
d
i
i
l
i
t
t
o
u
e
g
r
o
o
y
a
e
s
•		 L
P
h
I
I
b
i
l
i
t
a
r
g
e
a
s
e
r
a
n
•
i
f
i
2
0
1
2
t
t
t
p
r
e
p
a
r
a
o
n
o
r
s
a
r
n
P
h
I
I
b
l
i
d
t
a
s
e
c
o
m
p
e
o
n
a
n
•
(
/
)
P
h
I
I
I
d
2
0
1
3
2
0
1
4
t
t
a
s
e
s
a
r
e
n

World leading fran g biology and regen nchise in beta cell nerative medicine

Evotec´s CureBeta franchise

Investing in CureN Nephron

2

4

Kidney disease focused dr rug discovery

Evotec

1

  • •Proven regenerative medicine approach
  • • Experience and expertise in diabetic complications
  • • Fully integrated drug discovery platform

Unique kidney cell tools / capabilities Unique

  • • Customized kidney assays and animal models
  • • HCS capabilities for target identification

Harvard / Brigham and Woman's Hospital

  • •Prof. Andy McMahon
  • •Prof. Ben Humphreys
  • • World leading science in kidney disease

Paediatric Renal Medicine at the University of Bristol

  • • Prof. Moin A Saleem
  • Podocyte biology

3

Even higher upsid de if targets from Evotec

Drug discovery alliances – targets provided by EVT

P
t
a
r
n
e
r
s		 F
o
c
u
s
a
r
e
a		 U
i
d
f
E
t
p
s
e
o
r
v
v
o
e
c		 D
i
i
t
e
s
c
r
p
o
n
M
b
l
i
t
e
a
o
c
s
,		 +
+
+
+		 D
i
b
b
i
d
b
l
i
d
t
t
t
a
e
e
s
o
e
s
a
n
m
e
a
o
c
s
n
r
o
m
e
y
y
,
i
l
i
i
i
t
n
s
n
s
e
n
s
e
r
u
z		 f
f
R
h
d
i
€
7
t,
e
s
e
a
r
c
u
n
n
g
m
u
p
r
o
n
,
€
2
3
0
i
l
l
i
t
t
m
m
e
s
o
n
e
s
r
o
y
a
e
s
>
,
B
l
l
t
e
a
c
e
i
f
t
t
r
e
g
e
n
e
r
a
o
n
a
c
o
r		 +
+
+
+		 T
d
d
i
b
i
b
l
l
1
2
t
t
t
t
p
e
a
n
a
e
e
s
a
r
g
e
n
g
e
a
c
e
y
,
R
h
f
d
i
€
f
5
t,
m
a
s
s
e
s
e
a
r
c
n
n
g
m
p
r
o
n
u
u
,
,
€
2
0
i
i
l
l
l
i
5
t
t
t
m
m
m
e
e
s
s
o
o
n
n
e
e
s
s
r
o
y
a
e
s
>
,
P
i
a
n		 +
+
+		 V
R
A
i
1
t
t,
n
a
g
o
n
s
\$
P
f
b
d
l
l
i
f
1
0
t,
e
r
o
r
m
a
n
c
e
a
s
e
a
a
n
c
e
m
p
r
o
n
u
-
,
\$
1
0
i
l
l
i
7
t
t
m
m
e
s
o
n
e
s
r
o
y
a
e
s
>
,
R
e
s
p
o
n
s
e
d
i
i
t
p
r
e
c
o
n		 +
+		 P
f
b
d
l
l
i
f
d
e
r
o
r
m
a
n
c
e
a
s
e
a
a
n
c
e
o
c
s
e
o
n
u
-
,
d
l
f
d
i
i
t
t
e
e
o
p
m
e
n
o
r
e
s
p
o
n
s
e
p
r
e
c
n
g
v
b
i
k
d
i
l
d
f
i
i
l
o
m
a
r
e
r
s
n
s
c
o
s
e
n
a
n
c
a
s
;
u

Evo g as t e g o lving the glo Innovation Efficienoba eade l leader in ncy

Goals of Action Plan 2016

Key Performance Indicators

G
r
o
w		 D
b
l
l
b
2
0
1
6
t
t
o
u
e
r
e
v
e
n
u
e
s
a
e
s
y
•
O
1
%
i
i
d
l
h
i
t
t
5
t
t
t
p
e
r
a
e
a
a
p
p
r
o
x
o
p
e
r
a
n
g
n
c
c
o
m
e
a
n
a
c
c
e
e
r
a
e
c
a
s
-g
e
n
e
r
a
o
n
•
f
I
l
i
i
h
h
l
i
l
d
i
i
l
b
2
0
1
6
t
t
t
t
t
t
m
p
r
o
v
e
q
u
a
y
o
r
e
v
e
n
u
e
m
x
r
o
u
g
g
r
o
y
a
y,
m
e
s
o
n
e
a
n
s
e
r
v
c
e
n
c
o
m
e
a
e
s
y
•
I
t
n
n
o
a
e
v		 C
i
i
€
i
h
i
h
l
i
i
d
h
1
0
t
t
t
t
t
o
n
n
e
o
n
e
s
a
a
p
p
p
p
r
r
o
o
m
p
p
a
a
a
n
g
n
n
o
a
e
n
p
a
r
n
e
r
e
r
e
s
e
a
r
c
u
v
x
x
y
v
v
u
•
(
d
f
l
l
l
l
l
i
l
l
l
d
i
)
t
e
g
e
p
a
n
r
o
m
s
m
a
m
o
e
c
e
s
a
s
s
o
n
o
a
r
g
e
m
o
e
c
e
s
c
o
e
r
x
u
u
v
y
C
i
d
h
l
i
f
b
€
1
0
t
t
t
t
t
o
n
n
e
o
p
g
r
a
e
e
c
n
o
o
g
n
r
a
s
r
c
r
e
s
a
p
p
r
o
m
p
a
u
u
y
u
u
y
x
•
B
B
i
i
l
l
d
d
i
i
l
l
i
i
i
i
h
h
f
f
i
i
i
i
l
l
i
i
k
k
h
h
h
h
h
h
i
i
h
h
l
l
l
l
i
i
i
i
t
t
t
t
t
t
t
t
t
t
t
t
e
e
n
m
o
r
e
m
a
r
e
p
p
e
n
e
o
n
a
n
c
a
r
s
r
o
g
g
s
e
e
c
e
p
a
r
n
e
r
n
g
u
v
u
w
u
u
y
v
•
C
&
t
r
e
a
e
C
l
i
d
t
o
n
s
o
a
e		 A
i
l
i
i
i
i
k
l
i
d
i
t
t
t
t
t
t
t
c
e
p
a
r
c
p
a
e
n
s
r
a
e
g
c
m
a
r
e
e
c
o
n
s
o
a
o
n
v
y
•
O
i
i
h
h
l
d
l
i
t
t
p
m
s
e
s
a
r
e
o
e
r
v
a
u
e
c
r
e
a
o
n
•

Agenda

  • Evotec at a glance
  • Action Plan 2016 Innovation Efficiency
  • Financial strategy & Outlook

Positive trend of aunderlying busine all key g metrics reflect strength of ess

Key metrics for 2012

in € m

Strong growth and profitability and in d clear investment strategy drive nnovation

Key financials FY 2011: Co ondensed profit & loss statement (IFRS)

in €m

2
0
0
9
A
l
t
c
a
u		 2
0
1
0
A
l
t
c
a
u		 2
0
1
1
A
l
t
c
a
u		 %
s
v
A
l
0
1
t
c
a
u
R
e
e
n
e
s
v
u		 4
2
7		 5
5
3		 8
0
1		 4
5
%
+
G
i
r
o
s
s
m
a
r
g
n		 4
3
2
%		 4
4
1
%		 4
3
%
7
R
&
D
e
p
e
n
s
e
s
x
•		 2
0
9		 6
1		 8
4		 3
8
%
+		 S
i
t
r
o
n
g
o
r
g
a
n
c
S
G
&
A
e
x
p
e
n
s
e
s
•		 1
6
7		 1
6
0		 1
5
8		 1
%
-		 h
t
g
r
o
w
t
m
o
m
e
n
u
m
-
A
i
i
t
t
m
o
r
s
a
o
n
•		 0
5		 0
7		 1
7		 r
e
v
e
n
u
e
s
I
i
t
m
p
a
r
m
e
n
•		 1
8
2		 0
0		 2
1		 l
d
i
e
x
c
u
n
g
R
l
f
i
i
t
e
e
r
s
a
o
m
p
a
r
m
e
n
v
•		 (
) .
0
4		 0
0.		 (
(
)
)
1
1
5
5		 i
i
i
t
a
c
q
u
s
o
n
s
R
i
t
t
e
s
r
c
r
n
g
e
p
e
n
s
e
s
u
u
x
•		 4
8		 0
0		 0
0		 3
0
%
+
O
h
i
t
t
e
r
o
p
e
r
a
n
g
e
x
p
e
n
s
e
s
•		 (
)
0
1		 (
)
0
1		 3
3
O
i
i
(
l
)
t
p
e
r
a
n
g
n
c
o
m
e
o
s
s		 (
)
4
2
3		 1
7
+		 5
2
+		 2
0
4
%
+
N
i
(
l
)
t
e
n
c
o
m
e
o
s
s		 (
5
5
)
4		 3
0
+		 6
7
+		 1
2
3
%
+

Visit the Manfred EEigen Campus in Hamburg

Significant upgrading proc cesses at all sites

Sales representation (Boston, Tokyo) Operations & sales representation

1) Manfred Eigen (*1927), German biophysical chemist and work on a special measuring method of fast chemical react d one of the worldwide leading pioneers in biotechnology.In 1967, he won the Nobel Prize in Chemistry for his ions, which, until then, were considered to be immeasurable. He initiated the foundation of Evotec AG.

The right team to d industrialisationdeliver innovation, growth and

Management & sharehold der structure

Strong news flow to come

Outlook and next steps for r 2012 ff

Key milestones for 2012

E
V
T
E
1
t
x
e
c
u
e		 D
b
l
d
i
i
h
2
0
1
2
2
0
1
6
t
t
o
u
e
g
r
e
v
e
n
u
e
g
r
o
o
w
•
–
E
i
f
i
i
l
l
i
t
p
a
n
s
o
n
s
c
c
e
s
s
o
e
s
n
g
a
a
n
c
e
s
x
u
x
x
•
S
f
i
i
i
l
d
l
i
h
j
h
t
t
t
g
n
c
a
n
o
n
g
e
r
m
e
a
a
s
m
a
o
r
p
a
r
m
a
w
•
-
E
V
T
I
t
t
2
n
e
g
r
a
e		 A
l
i
i
i
i
f
f
i
i
i
i
d
d
h
h
l
l
/
/
d
d
i
i
l
l
i
2
2
t
t
t
t
t
t
t
t
t
t
e
a
s
s
g
n
c
a
n
n
e
n
e
g
r
a
e
e
c
n
o
o
g
s
e
a
s
e
a
a
n
c
e
s
w
w
y
•
f
/
D
l
i
i
i
i
d
l
d
l
i
i
l
l
i
i
l
i
l
t
t
t
e
e
r
s
g
n
c
a
n
a
n
a
a
c
c
e
e
r
a
e
p
r
e
c
n
c
a
c
n
c
a
m
e
s
o
n
e
s
v
•
S
f
h
i
l
i
i
i
i
t
t
t
o
w
o
p
e
r
a
o
n
a
s
y
n
e
r
g
g
e
s
o
r
e
c
e
n
a
c
q
u
s
o
n
s
•
E
V
T
I
t
3
n
n
o
a
e
v		 A
l
i
d
l
f
l
1
t
t
t
t
t
e
a
s
s
r
a
e
g
c
e
a
o
r
e
a
r
a
s
s
e
s
y
•
f
f
f
f
(
)
E
d
i
i
l
l
l
i
A
i
b
d
i
t
t
p
a
n
o
e
r
n
g
n
o
a
r
g
g
e
r
m
o
e
c
e
s
o
e
r
n
g
e
g
n
o
e
s
x
u
•
C
(
C
)
i
l
i
i
i
X
t
o
m
m
e
r
c
a
s
e
n
n
o
v
a
o
o
n
e
g
u
r
e
•
,
…
P
h
I
I
I
d
i
D
i
P
d
P
h
I
I
b
i
h
i
A
D
d
2
7
7
t
t
t
t
t
a
s
e
a
a
n
a
e
p
p
a
n
a
s
e
s
a
r
n
p
r
o
c
w
u
•
d
l
h
i
t
t
e
e
o
p
m
e
n
p
a
r
n
e
r
s
p
p
v

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Capital/Financing Update 2026
May 12
Regulatory Filings 2026
May 7
Regulatory Filings 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Regulatory Filings 2026
May 5
Regulatory Filings 2026
May 4
Regulatory Filings 2026
Apr 30
Report Publication Announcement 2026
Apr 29
Major Shareholding Notification 2026
Apr 28
View all filings →